GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ipca Laboratories Ltd

Ipca Laboratories Q2 FY27 Standalone Profit up 27.08% to Rs. 387.29 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Nov 2026, 01:45 PM IST  ·  BSE ID: 9150be75-41ec-4919-bcb3-065f1b99314f
View Original BSE Filing (PDF)
💡
In Simple Terms
Ipca Laboratories announced its financial results for Q2 FY27, reporting increased revenue and profit for the quarter and half year.
🤖 AI Summary
  • Ipca Laboratories' standalone revenue from operations for Q2 FY27 reached Rs. 2,255.61 Crores.
  • Profit for Q2 FY27 from continuing operations stood at Rs. 387.29 Crores, an increase of 27.08% YoY.
  • Half-year ended September 30, 2026, standalone revenue was Rs. 4,374.85 Crores.
  • Half-year standalone profit from continuing operations was Rs. 760.58 Crores, up 34.19% YoY.
  • Total Equity reported as of September 30, 2026, was Rs. 8,576.48 Crores.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
2,255.61 Crores
16.85
Profit for the period (Q2 FY27)
387.29 Crores
27.08
Revenue from operations (Half Year FY27)
4,374.85 Crores
18.97
Profit for the period (Half Year FY27)
760.58 Crores
34.19
Basic/Diluted EPS (Q2 FY27)
15.27 Crores
27.14
🏢 How This Affects the Company
📈
Business Impact
The Pharmaceuticals segment remains the sole operating segment, indicating no immediate diversification from the core business. Strong revenue growth suggests sustained demand for the company's products.
💰
Financial Impact
Net profit for Q2 FY27 increased by 27.08% YoY, contributing to a 34.19% YoY rise in half-year profit. This indicates improved profitability and operational efficiency for the reported periods.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 27.08% increase in Q2 FY27 profit to Rs. 387.29 Crores.
🔍
Management Signal
The financial results indicate management's focus on driving revenue growth and improving profitability within its core Pharmaceuticals segment.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor sustained revenue growth above Rs. 2,200 Crores.
Update on Krebs Biochemicals & Industries Ltd amalgamation approval process.
Cash flow from operations — assess stability against investments and financing activities.
LOW RISK No new significant risks identified; strong financial performance reported.
💡 Investor Takeaway
Ipca Laboratories reported Q2 FY27 standalone profit from continuing operations of Rs. 387.29 Crores, a 27.08% YoY increase. Half-year profit rose 34.19% YoY to Rs. 760.58 Crores. Revenue from operations for Q2 FY27 was Rs. 2,255.61 Crores, growing 16.85% YoY.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone profit for Q2 FY27 increased by 27.08% to Rs. 387.29 Crores, demonstrating improved quarterly profitability.
  • Half-year standalone profit rose by 34.19% to Rs. 760.58 Crores, reflecting strong performance over the six-month period.

⚠️ Concerns

  • Other Income decreased by 13.64% YoY to Rs. 18.92 Crores in Q2 FY27, indicating a decline in non-operating income sources.
  • Cash and cash equivalents decreased from Rs. 311.51 Crores as of March 31, 2026, to Rs. 84.60 Crores as of September 30, 2026.
📅 Company Track Record
Ipca Laboratories' Q2 FY27 net profit of Rs. 387.29 Crores marks a 27.08% YoY increase, following a prior Q2 FY26 net profit of Rs. 304.74 Crores. This indicates continued growth in the company's quarterly profitability.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Ipca Laboratories' standalone revenue in Q2 FY27?
Ipca Laboratories reported standalone revenue from operations of Rs. 2,255.61 Crores for the quarter ended September 30, 2026 (Q2 FY27).
What was Ipca Laboratories' standalone profit after tax for Q2 FY27?
The standalone profit for the period from continuing operations for Ipca Laboratories in Q2 FY27 was Rs. 387.29 Crores, up from Rs. 304.74 Crores in Q2 FY26.
How did Ipca Laboratories' half-year revenue perform up to September 30, 2026?
Ipca Laboratories' standalone revenue from operations for the half-year ended September 30, 2026, was Rs. 4,374.85 Crores, compared to Rs. 3,677.22 Crores for the same period last year.
What was the Basic/Diluted EPS for Ipca Laboratories in Q2 FY27?
The Basic/Diluted Earnings Per Share (EPS) for Ipca Laboratories for Q2 FY27 was Rs. 15.27, based on a face value of Rs. 1/- per share.
What is the status of the Krebs Biochemicals & Industries Ltd amalgamation?
The Board resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the company, with an appointed date of April 1, 2026; however, no effect has been given in these financial results pending consents/approvals.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.